Loading
NASDAQHealthcareBiotechnology
Latest quote
$35.2698
−$0.9902 · -2.73%
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.
Regular session
$35.2698
−$0.9902 · -2.73%
Regular session · ET · Market data may be delayed.
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.
Day range
Current $35.2698
52-week range
Current $35.2698
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
62
Undervalued
Sentiment
64
Bullish
Risk
37
Moderate Risk
Momentum
54
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.
Day range
Current $35.2698
52-week range
Current $35.2698
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 218.71M USD | 7M USD | 23.39M USD | 50.93M USD | 27.94M USD |
| Cost of goods sold | 314.7M USD | 3.83M USD | 4.01M USD | 2.1M USD | 1.73M USD |
| Gross profit | −95.99M USD | 3.17M USD | 19.38M USD | 48.83M USD | 26.22M USD |
| Research and development | 314.7M USD | 294.67M USD | 129.51M USD | 89.54M USD | 58.16M USD |
| Selling, general, and administrative | 63.32M USD | 35.47M USD | 24.3M USD | 21.8M USD | 18.33M USD |
| Operating expenses | 63.32M USD | 330.14M USD | 153.81M USD | 111.33M USD | 76.48M USD |
| Interest income | 45.62M USD | 52.5M USD | 21.47M USD | 3.85M USD | 506K USD |
| Depreciation and amortization | 4.59M USD | 3.83M USD | 4.01M USD | 2.1M USD | 1.73M USD |
| Operating income | −159.31M USD | −326.98M USD | −134.43M USD | −62.5M USD | −50.27M USD |
| Net income | −113.7M USD | −274.48M USD | −112.96M USD | −58.66M USD | −49.76M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI119.27M0.01%2.3T USD0.03%$379.53-0.39%
iShares Russell 2000 ETFIWM85.97M0.11%78.56B USD0.19%$274.74-1.07%
State Street SPDR S&P Biotech ETFXBI60.87M0.59%10.08B USD0.35%$146.55-2.45%
Vanguard Extended Market ETFVXF43.59M0.04%95.4B USD0.05%$231.37-0.91%
iShares Biotechnology ETFIBB24.88M0.24%10.4B USD0.44%$197.52-2.86%
Dimensional - US Small Cap ETFDFAS23.29M0.07%33.66B USD0.31%$77.34-0.74%
Vanguard Russell 2000 ETFVTWO19.33M0.11%18B USD0.06%$110.96-1.11%
Schwab U.S. Small-Cap ETFSCHA18.35M0.08%21.7B USD0.03%$32.295-0.97%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
